This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

OraSure Technologies And Roche Announce FDA 510(k) Clearance For Four Fully Automated Oral Fluid Drugs Of Abuse Assays

BETHLEHEM, Pa., March 3, 2011 (GLOBE NEWSWIRE) -- OraSure Technologies, Inc. (Nasdaq:OSUR) and Roche announced today that the U.S. Food and Drug Administration ("FDA") has granted the Companies 510(k) clearance on four homogeneous fully automated oral fluid drugs of abuse assays developed to be used exclusively as part of OraSure's Intercept ® Oral Fluid Drug Testing System. The cleared oral fluid assays include Phencyclidine (PCP), Cocaine, Opiates and Methamphetamine.

The oral fluid assays use Roche's KIMS (kinetic interaction of micro-particles in solution) technology and were jointly developed under an agreement previously signed by the parties. These assays are designed to run on various clinical chemistry automated analyzers, which are intended to allow oral fluid samples to be processed with the same efficiency as current fully automated urine-based drug tests.

"We are very pleased to announce this significant milestone in our joint effort with Roche to develop and market these important drugs of abuse assays," said Douglas A. Michels, President and CEO of OraSure Technologies. "The combination of Roche's industry leadership in lab instrumentation and reagent chemistry and our leadership in oral fluid technology and sample collection devices has enabled us to bring to market a breakthrough system that will have an immediate and positive impact on laboratory efficiency for drugs of abuse testing."

"The approval of this first set of fully automated oral fluid drugs of abuse assays demonstrates the strengths and experience of both companies," said Frank G. Sieben, SVP and Life Cycle Leader of Roche Professional Diagnostics. "Specifically the technologies and expertise of our collective research and development teams will enable us to provide novel high throughput oral fluid drug testing solutions."

The Companies anticipate the first four assays to be available for sale later this year. Several additional assays are also in development and are currently in varying stages of submission with the FDA.

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG

Markets

Chart of I:DJI
DOW 17,689.86 -56.12 -0.32%
S&P 500 2,103.84 -4.79 -0.23%
NASDAQ 5,128.2810 -0.5040 -0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs